Posaconazole: A new antifungal weapon

Reviews on Recent Clinical Trials

Volumn 6, Issue 3, 2011, Pages 204-219

  Aperis, Georgios ^a   Alivanis, Polichronis ^a  

^a General Hospital of Rhodes   (Greece)

Author keywords

Aspergillus spp.; Candida spp.; Coccidioides spp.; Cryptococcus neoformans; Fusarium spp. posaconazole; Prophylaxis; Zygomycetes

Indexed keywords

ALPRAZOLAM; AMPHOTERICIN B; ANIDULAFUNGIN; ASTEMIZOLE; CASPOFUNGIN; CIMETIDINE; CISAPRIDE; CYCLOSPORIN; DIGOXIN; ECHINOCANDIN; EFAVIRENZ; ERGOT ALKALOID; FAMOTIDINE; FLUCONAZOLE; HALOFANTRINE; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; MICAFUNGIN; OMEPRAZOLE; PHENYTOIN; PIMOZIDE; PLACEBO; POSACONAZOLE; QUINIDINE; RANITIDINE; RAPAMYCIN; RIFABUTIN; TACROLIMUS; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIFUNGAL RESISTANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; ASPERGILLUS; AUTONOMIC DYSFUNCTION; BILIRUBIN BLOOD LEVEL; CANDIDA; CANDIDIASIS; CLINICAL TRIAL (TOPIC); CONSTIPATION; CRYPTOCOCCUS NEOFORMANS; DIARRHEA; DIZZINESS; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FATIGUE; FLUSHING; FUSARIUM; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GOLD STANDARD; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOBILIARY DISEASE; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION RISK; LIVER CELL DAMAGE; LIVER FUNCTION TEST; MUSCULOSKELETAL DISEASE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; QT PROLONGATION; RASH; SALVAGE THERAPY; SCEDOSPORIUM; SIDE EFFECT; SOMNOLENCE; SURVIVAL; SYSTEMIC MYCOSIS; VITAL SIGN; VOMITING; XEROSTOMIA; ZYGOMYCETES; ZYGOMYCOSIS;

ANTIFUNGAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; HUMANS; IMMUNOCOMPROMISED HOST; KIDNEY DISEASES; MYCOSES; OPPORTUNISTIC INFECTIONS; TRIAZOLES;

EID: 80051753684     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/157488711796575595     Document Type: Article

References (121)

1. Chandrasekar PH, Cutright JL, Manavathu EK. Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999. Diagn Microbiol Infect Dis 2001; 41(4): 211-4.
2. Armstrong D. Problems in management of opportunistic fungal diseases. Rev Infect Dis 1989; 11 Suppl 7: S1591-S1595.
3. Khoo SH, Denning DW. Invasive aspergillosis in patients with AIDS. Clin Infect Dis 1994; 19 Suppl 1: S41-S48.
4. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001; 150(3): 101-15.
5. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35(5): 627-30.
6. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34(7): 909-17.
7. Oakley KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41(7): 1504-7.
8. Castaldo P, Stratta RJ, Wood RP, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991; 126(2): 149-56.
9. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26(4): 781-803; quiz 4-5.
10. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326(13): 845-51.
11. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33(1): 23-32.
12. Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 2001; 14(6): 685-91.
13. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996; 9(4): 499-511.
14. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24(6): 1122-8.
15. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998; 31(1): 327-32.
16. Nguyen MH, Peacock JE, Jr., Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100(6): 617-23.
17. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28(5): 1071-9.
18. Perfect JR. Antifungal resistance: the clinical front. Oncology (Williston Park) 2004; 18(14 Suppl 13): 15-22.
19. Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2004; 39 Suppl 1: S38-S43.
20. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32(3): 358-66.
21. Marty F CL, Marasco WA, Rubin RH, Baden LR. Breakthrough zygomycosis in allogeneic hematopoietic stem cell transplant recipients who received voriconazole as prophylaxis or empiric therapy: 2003. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago, IL.
22. Hossain MA, Ghannoum MA. New investigational antifungal agents for treating invasive fungal infections. Expert Opin Investig Drugs 2000; 9(8): 1797-813.
23. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6): 408-15.
24. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002; 15(6): 569-74.
25. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33(5): 641-7.
26. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51(1): 45-52.
27. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13(2): 236-301.
28. Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003; 37(2): 221-9.
29. Pagano L, Ricci P, Tonso A, et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto). Br J Haematol 1997; 99(2): 331-6.
30. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 1999; 159(12): 1301-9.
31. Bal AM. The echinocandins: three useful choices or three too many? Int J Antimicrob Agents Jan; 35(1): 13-8.
32. Noxafil. Product label information. 09/08/2010, http://www.accessdata.fda.gov/Accessed on 02/01/2011
33. Noxafil. European Medicines Agency., 08/2010. http://ema.europa.eu/ Accessed on 02/01/2011
34. Cacciapuoti A, Gurnani M, Halpern J, Norris C, Patel R, Loebenberg D. Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo. Antimicrob Agents Chemother 2005; 49(2): 638-42.
35. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47(9): 2788-95.
36. Aperis G, Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs 2006 Jun; 15(6): 579-602.
37. Chiou CC, Groll AH, Walsh TJ. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. Oncologist 2000; 5(2): 120-35.
38. Hitchcock CA, Dickinson K, Brown SB, Evans EG, Adams DJ. Interaction of azole antifungal antibiotics with cytochrome P-450- dependent 14 alpha-sterol demethylase purified from Candida albicans. Biochem J 1990 Mar 1; 266(2): 475-80.
39. Ghannoum MA, Kuhn DM. Voriconazole -- better chances forpatients with invasive mycoses. Eur J Med Res 2002; 7(5): 242-56.
40. Geber A, Hitchcock CA, Swartz JE, et al. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob Agents Chemother 1995; 39(12): 2708-17.
41. Hachem RY, Raad I, Afif C et al. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SHC56592) in the treatment of invasive fungal infections refractory or intolerant to standard therapy: 2000. In: 40TH Interscience Conference on Antimicrobial Agents and Chemptherapy; 2000; Toronto, ON, Canada.
42. Raad I Chapman S, Bradsher R, Morrison V, et al. Posaconazole salvage therapy for invasive fungal infections: 2004. In: 44TH Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004; Washington, DC.
43. Anstead GMM, Graybill JR. Control of Candida glabrata endovascular TIPS infection with posaconazole. In: 15TH Congress of the International Society For Human and Animal Mycosis; 2003; San Antonio, TX.
44. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006 Apr 15; 42(8): 1179-86.
45. Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV clinical trials 2007 Mar-Apr; 8(2): 86-97.
46. Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis 2007 Feb 15; 44(4): 607-14.
47. Walsh TJ, Patterson T., Langston A et al. Posaconazole for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional therapy: an externally controlled blinded trial. Blood 2003; 102: 105a-106a.
48. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44(1): 2-12.
49. Alexander BD, Perfect JR, Daly JS, et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 2008; 86(6): 791-6.
50. Lellek H, Waldenmaier D, Dahlke J, et al. Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients. Mycoses; 54 Suppl 1: 39-44.
51. Tissot-Dupont H BS, Pham T, Blancard A, Lafforgue P. Aspergillus flavus chondrocostal osteomyelitis treated with posaconazole: a case study. In: Joint Meeting of the 9th Congress of the European Confederation of Medical Mycology and the 7th Trends in Invasive Fungal Infections; 2003 Sep 28-Oct 1; Amsterdam, Netherlands.
52. Pittisuttithum P Gaona-Flores V, Negroni R et al. Efficacy of posaconazole in treatment of central nervous system fungal infections: results from an open-label study. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago, IL.
53. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005.
54. Greenberg RN Herbrecht R, Langston A et al. Posaconazole therapy for refractory invasive zygomycosis. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago, IL.
55. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50(1): 126-33.
56. van Burik JAH, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42: e61-e65.
57. Greenberg RN, Scott LJ, Vaughn HH, Ribes JA. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 2004; 17(6): 517-25.
58. Tobon AM, Arango M, Fernandez D, Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 2003; 36(11): 1488-91.
59. Ide L, Buysschaert I, Demuynck H, et al. Zygomycosis in neutropenic patients with past Aspergillus infection: a role for posaconazole? Clin Microbiol Infect 2004; 10(9): 862-3.
60. Cornely OA, Vehreschild JJ, Rüping MJGT. Current experience in treating invasive zygomycosis with posaconazole. Clin Microbiol Infect 2009; 15(Suppl. 4): 1-5.
61. Groll AH. Efficacy and safety of antifungals in pediatric patients. Early Hum Dev 2001; 87 Supp 1: S71-S74
62. Catanzaro A, Cloud GA, Stevens DA, et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin Infect Dis 2007; 45(5): 562-8.
63. Stevens DA, Rendon A, Gaona-Flores V, et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 2007; 132(3): 952-8.
64. Anstead GM, Corcoran G, Lewis J, Berg D, Graybill JR. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005; 40(12): 1770-6.
65. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005; 40(11): 1684-8.
66. Herbrecht R Mullane K, Catanzaro A, Greenberg R, Tissot-Dupont H, Gallais H, Moore T, Corcoran G, Pedicone L. Posaconazole as salvage therapy for invasive fungal infections unresponsive to voriconazole: a case series. In: 44th Interscience Conference on Antimicrobial agents and Chemotherapy; 2004; Washington, DC.
67. Raad, II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42(10): 1398-403.
68. Sponsel WE, Graybill JR, Nevarez HL, Dang D. Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol 2002; 86(7): 829-30.
69. Riddell JIV, Comer GM, Kauffman CA. Treatment of endogenous funal endophthalmitis: focus on new antifungal agents. Clin Infect Dis 2011; 1-6.
70. Negroni R, Tobon, AM, Bustamante M, et al. Posaconazole treatment of mycetoma and chromoblastomycosis. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago, IL.
71. Restrepo A, Tobon A, Clark B, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect 2007; 54(4): 319-27.
72. Negroni R, Tobon A, Bustamante B, Shikanai-Yasuda MA, Patino H, Restrepo A. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Revista do Instituto de Medicina Tropical de Sao Paulo 2005; 47(6): 339-46.
73. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002; 34(12): 1648-50.
74. Al-Abdely HM, Alkunaizi A, Al-Tawfig J, et al. Successful treatment of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with a new triazole, posaconazole (SCH 56592). In: 13th European Congress of Clinical Microbiology and Infectious Diseases.; 2003; Glasgow, Scotland.
75. Herbrecht R, Kessler R, Kravanja C, Meyer MH, Waller J, Letscher-Bru V. Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient. J Heart Lung Transplant 2004; 23(12): 1451-4.
76. Lewis J, Anstead, G., Graybill, J. Successful treatment of disseminated coccidioidomycosis (Coccidioides immitis) with posaconazole. In: 15th Congress of the International Society for Human and Animal Mycosis; 2003; San Antonio, TX.
77. Negroni R, Helou, S., Petri, N, et al. Successful posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera: a case report. In: 15th Congress of the International Society for Human and Animal Mycosis; 2003; San Antonio, TX.
78. Herbrecht R, Letscher-Bru V, Fohrer C, et al. Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B. Eur J Clin Microbiol Infect Dis 2002; 21(11): 814-7.
79. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356(4): 335-47.
80. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356(4): 348-59.
81. Hahn J, Stifel F, Reichle A, Holler E, Andreesen R. Clinical experience with posaconazole prophylaxis-a retrospective analysis in a haematological unit. Mycoses 2011; 54 Suppl 1: 12-16.
82. Hachem RY, Langston AA, Graybill JR, et al. Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. J Antimicrob Chemother 2008; 62(6): 1386-91.
83. Courtney RD, Sansone A, Radwanski E, et al. Relative oral bioavailability of three formulations of posaconazole in healthy volunteers: basis for clinical development of the suspension. In: 13th Congress of Clinical Microbiology and Infectious Diseases. 2003; Glasgow, Scotland.
84. Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005; 45(2): 185-92.
85. Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. Pharmaokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet 2010; 49(6): 379-96.
86. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57(2): 218-22.
87. Herbrecht R, Nivoix Y, Fohrer C, Natarajan-Ame S, Letscher-Bru V. Management of systemic fungal infections: alternatives to itraconazole. J Antimicrob Chemother 2005; 56 Suppl 1: i39-i48.
88. Lipp HP. Clinical pharmacodynamic and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br J Clin Pharmacol 2010; 70(4): 471-80.
89. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44(2): 211-20.
90. Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007; 51(2): 495-502.
91. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004; 48(3): 804-8.
92. Jain R, Pottinger P. The effect of gastric Acid on the absorption of posaconazole. Clin Infect Dis 2008; 46: 1627; author reply -8.
93. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53(3): 958-66.
94. Dodds Ashley ES, Varkey JB, Krishna G, et al. Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. Antimicrob Agents Chemother 2009; 53(7): 2960-4.
95. Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 2008; 28(10): 1223-32.
96. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007; 27(12): 1627-36.
97. Farowski F, Cornely OA, Vehreschild JJ, et al. Intracellular concentrations of posaconazole in different compartments of peripheral blood. Antimicrob Agents Chemother 54(7): 2928-31.
98. Conte JE, Jr., Golden JA, Krishna G, McIver M, Little E, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob Agents Chemother 2009; 53(2): 703-7.
99. Krishna G, Beresford E, Ma L, et al. Skin concentrations and pharmacokinetics of posaconazole after oral administration. Antimicrob Agents Chemother 2010; 54(5): 1807-10.
100. Ruping MJ, Albermann N, Ebinger F, et al. Posaconazole concentrations in the central nervous system. J Antimicrob Chemother 2008; 62(6): 1468-70.
101. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two way crossover study. Eur J Pharm Sci 2004; 21: 645-53
102. Krieter P, Flannery B, Musick T, et al. Pharmacokinetics and excretion of 14C posaconazole following oral administration in healthy male subjects. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002; San Diego, CA.
103. Ezzet F, Wexler, D, Courtney, R. et al. Comparative bioavailability of oral posaconazole in different dosage regimen: a population pharmacokinetic analysis. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago, IL.
104. Ullmann AJ, Cornely OA, Burchardt A, et al. Safety and efficacy of posaconazole in a pharmacokinetic study in patients with febrile neutropenia of refractory invasive fungal infections. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago, IL.
105. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50(2): 658-66.
106. Skiest D, Ward D, Northland A, Reynes J, Greaves W. Treatment of azole-refractory candidiasis in HIV disease. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999; San Fransisco, CA.
107. Restrepo A Clark B, Graham DR et al. Successful treatment of disseminated and acute pulmonary histoplasmosis with posaconazole. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago, IL.
108. Sansone A Courtney R, Brundage T, Laughlin M. Safety and tolerability of posaconazole: evaluation of 18 controlled healthy volunteer studies. In: 44th International Conference on Antimicrobial Agents and Chemotherapy; 2004; Washington, DC.
109. Raad, II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 42(12): 1726-34.
110. Gil-Lamaignere C, Hess R, Salvenmoser S, Heyn K, Kappe R, Muller FM. Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes. J Antimicrob Chemother 2005; 55(6): 1016-9.
111. Pfaller MA, Diekema DJ. Unusual fungal and pseudofungal infections of humans. J Clin Microbiol 2005; 43(4): 1495-504.
112. Sansone A, Bella D, Statkevitch P, et al. Effect of posaconazole on the pharmacokinetics of tacrolimus in healthy volunteers. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago, IL.
113. Courtney RD, Statkevitch P, Laughlin M. Effect of posaconazole on the pharmacokinetics of cyclosporine. In: 41 st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago, IL.
114. Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36(10): 2950-6.
115. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20(4): 121-36.
116. Al-Abdely HM, Najvar LK, Bocanegra R, Graybill JR. Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana. Antimicrob Agents Chemother 2005; 49(5): 1701-7.
117. Gubbins PO, Heldenbrand S. Clinically relevant drug interactionsof current antifungal agents. Mycoses 2010; 53(2): 95-113.
118. Haidar C, Jeha S. Drug interactions in childhood cancer. Lancet Oncol 2011; 12(1): 92-9.
119. Statkevich P, Courtney RD, Laughlin M, et al. Eds. Potential for a drug interaction between posaconazole and phenytoin: 2001. In: 41th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago, IL.
120. Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47(10): 3149-54.
121. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000; 46(2): 229-34.